|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-6-5
|
|
pubmed:abstractText |
Carboplatin is a second-generation platinum compound that in combination with etoposide and intermediate doses of cytarabine, in early clinical trials has demonstrated high efficacy in refractory acute myelogenous leukemia and the blastic phase of CML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9093727-Adolescent,
pubmed-meshheading:9093727-Adult,
pubmed-meshheading:9093727-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9093727-Carboplatin,
pubmed-meshheading:9093727-Child,
pubmed-meshheading:9093727-Cytarabine,
pubmed-meshheading:9093727-Etoposide,
pubmed-meshheading:9093727-Female,
pubmed-meshheading:9093727-Humans,
pubmed-meshheading:9093727-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:9093727-Male,
pubmed-meshheading:9093727-Remission Induction
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
|
|
pubmed:affiliation |
Department of Human Biopathology, University La Sapienza, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
